Marathon Asset Management Ltd Cuts Holdings in Bio-Rad Laboratories, Inc. (NYSE:BIO)

Marathon Asset Management Ltd lessened its position in shares of Bio-Rad Laboratories, Inc. (NYSE:BIO - Free Report) by 9.6% in the first quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 60,655 shares of the medical research company's stock after selling 6,472 shares during the quarter. Marathon Asset Management Ltd owned 0.22% of Bio-Rad Laboratories worth $14,774,000 at the end of the most recent reporting period.

Other institutional investors also recently bought and sold shares of the company. Amalgamated Bank lifted its holdings in shares of Bio-Rad Laboratories by 2.0% in the fourth quarter. Amalgamated Bank now owns 9,214 shares of the medical research company's stock worth $3,027,000 after buying an additional 181 shares in the last quarter. Oppenheimer Asset Management Inc. increased its holdings in Bio-Rad Laboratories by 1.7% in the 4th quarter. Oppenheimer Asset Management Inc. now owns 2,714 shares of the medical research company's stock valued at $892,000 after acquiring an additional 45 shares during the last quarter. Proficio Capital Partners LLC bought a new position in shares of Bio-Rad Laboratories during the 4th quarter valued at about $9,820,000. Fisher Asset Management LLC boosted its holdings in shares of Bio-Rad Laboratories by 15.2% during the 4th quarter. Fisher Asset Management LLC now owns 106,871 shares of the medical research company's stock valued at $35,108,000 after purchasing an additional 14,135 shares during the last quarter. Finally, US Bancorp DE grew its position in shares of Bio-Rad Laboratories by 0.9% during the fourth quarter. US Bancorp DE now owns 9,680 shares of the medical research company's stock valued at $3,180,000 after purchasing an additional 87 shares in the last quarter. Institutional investors own 65.24% of the company's stock.

Analyst Upgrades and Downgrades

BIO has been the subject of a number of research reports. Wall Street Zen lowered Bio-Rad Laboratories from a "buy" rating to a "hold" rating in a research note on Sunday, June 8th. UBS Group lowered their target price on Bio-Rad Laboratories from $355.00 to $310.00 and set a "buy" rating for the company in a research report on Friday, May 2nd. Wells Fargo & Company reduced their price target on shares of Bio-Rad Laboratories from $260.00 to $245.00 and set an "equal weight" rating on the stock in a research report on Monday, June 9th. Citigroup dropped their price objective on shares of Bio-Rad Laboratories from $400.00 to $350.00 and set a "buy" rating for the company in a research note on Friday, May 2nd. Finally, Royal Bank Of Canada reduced their target price on shares of Bio-Rad Laboratories from $409.00 to $392.00 and set an "outperform" rating on the stock in a report on Friday, May 2nd. Two analysts have rated the stock with a hold rating and three have issued a buy rating to the company's stock. According to data from MarketBeat.com, Bio-Rad Laboratories has a consensus rating of "Moderate Buy" and a consensus price target of $324.25.

Bio-Rad Laboratories Trading Up 2.8%

Shares of NYSE:BIO traded up $6.84 on Tuesday, hitting $248.16. 272,293 shares of the company's stock were exchanged, compared to its average volume of 342,779. The stock has a market capitalization of $6.75 billion, a price-to-earnings ratio of -3.26 and a beta of 0.93. Bio-Rad Laboratories, Inc. has a 12 month low of $211.43 and a 12 month high of $387.99. The company has a debt-to-equity ratio of 0.18, a current ratio of 5.99 and a quick ratio of 4.43. The business's 50 day simple moving average is $235.54 and its two-hundred day simple moving average is $273.67.

Bio-Rad Laboratories (NYSE:BIO - Get Free Report) last announced its quarterly earnings data on Thursday, May 1st. The medical research company reported $2.54 earnings per share for the quarter, beating analysts' consensus estimates of $1.73 by $0.81. The company had revenue of $585.40 million during the quarter, compared to analyst estimates of $573.01 million. Bio-Rad Laboratories had a negative net margin of 85.16% and a positive return on equity of 4.32%. The firm's revenue for the quarter was down 4.2% on a year-over-year basis. During the same quarter last year, the business posted $2.30 EPS. Analysts anticipate that Bio-Rad Laboratories, Inc. will post 10.81 EPS for the current fiscal year.

Bio-Rad Laboratories Profile

Bio-Rad Laboratories, Inc manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety markets.